MedTrace Logo

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

NCT05453487 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2022-07-29

No results posted yet for this study

Summary

Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.

Conditions

Interventions

BIOLOGICAL

coadministration

the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine

BIOLOGICAL

COVID-19 vaccine

received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)

BIOLOGICAL

rabies vaccine

received three dose of rabies vaccine

Sponsors & Collaborators

  • Guizhou Center for Disease Control and Prevention

    collaborator OTHER

  • Shaanxi Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • Changchun Institute of Biological Products Co., Ltd.

    collaborator INDUSTRY

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Ruizhi Zhang · Guizhou Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2022-10-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453487 on ClinicalTrials.gov